# RNN 2nd Gen Model AbbVie Inc. Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
Dec. 14, 2020
Deal entry on
Dec. 14, 2020
37.42%Expected margin
78.57% successful of 14 deals
$ 114.67 Last close price
at 29-oct-2021


Model's trade recommendations No return for period yet

1.45% Annual return

$159.38B Market Cap

β 1.59  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period
52wk return 34.05%
52wk Range
Sortino ratio 0.31
Sharpe ratio 0.22
Norm. RMSE 34.85%
Downside risk 4.13%
Volatility 0.00%
  • 3.84 (3.83%) Div (Yield)
  • BUY Analysts consensus recommendation

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for AbbVie Inc. (ABBV) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since April 29, 2015.

Market data for ABBV model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ABBV.

Model is being retrained on a regular basis.

Float 1587M
P/E 16.24
Shares Outstanding 1588M
% Held by Insiders 0.07%
% Held by Institutions 70.29%
EPS (last reported FY) $5.60
EPS (last reported Q) $1.87
EPS, estimated (last reported Q) $1.80
Total revenues $28 B
Net income $5 B